Geron Corporation (GERN) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star, then the number one on your telephone keypad. I would now like to turn the call over to David Borah, Head of Investor Relations. David, please go ahead. Good morning, everyone. Welcome to Geron Corporation's second quarter 2025 earnings conference call. Before we begin, please note that during the course of this presentation and question and answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those relating to the launch, commercial opportunity, therapeutic potential of Ritello, anticipated clinical and commercial events and related timelines, the sufficiency of Geron's financial resources, and other statements that are not historical facts. Actual events or results could differ materially. Therefore, I refer you to the discussion under the heading risk factors in Geron's most recent periodic report filed with the SEC, which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements and our future updates to those risk factors. Geron undertakes no duty or obligation to update our forward-looking statements. With that, I'll turn the call over to Dawn Beer, Interim President and Chief Executive Officer. Thank you, Dave, and good morning to everyone on the call. I'll begin on slide four. Earlier today, the company issued a press release announcing the appointment of Geron's new president and CEO, Harout Samirjian. He has joined today's call and will provide brief comments before we open the call for Q&A. I'm also joined by several members of our mana...